ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings results on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. ProPhase Labs had a net margin of 262.61% and a return on equity of 88.57%. The business had revenue of $1.91 million for the quarter.

ProPhase Labs (NASDAQ:PRPH) traded up 1.47% during mid-day trading on Friday, reaching $2.07. 12,045 shares of the company’s stock traded hands. The firm has a market cap of $35.51 million, a price-to-earnings ratio of 0.83 and a beta of 0.07. The firm’s 50-day moving average price is $2.06 and its 200 day moving average price is $2.02. ProPhase Labs has a one year low of $1.70 and a one year high of $2.45.

TRADEMARK VIOLATION WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at

ProPhase Labs Company Profile

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Earnings History for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.